Oncternal Therapeutics, Inc. (ONCT), a clinical-stage biopharmaceutical company specializing in manufacturing unique oncology therapies, announced the latest interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial, to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.
At last check in after-market trading, shares of Oncternal Therapeutics Inc. (ONCT) were up 13.13% at $6.29. ONCT’s stock closed the last session at $5.56, decreasing -4.14% or -$0.24. Shares of the company fluctuated between $5.37 and $5.67 throughout the day. The shares of Oncternal Therapeutics Inc. have advanced 9.45% in the last five days; however, they have lost -3.30% over the last month.
Updated Interim Data
In the CIRLL study, cirmtuzumab, a potential anti-ROR1 monoclonal antibody, is being assessed to be used with ibrutinib in patients affected with MCL and CLL. The clinical trial is being supervised in association with the UC San Diego School of Medicine and is partly funded by the California Institute for Regenerative Medicine.
Patients consisted of heavy risk factors and were stiffly pre-treated at study entry, 70% with a high Ki-67 proliferative index, 15% with intermediate to high prognostic score, and an average of two methodical previous therapies.
The ORR of 83% (with 15 out of a total 18 patients assessed), which was inclusive freshly registered patients with comparatively short follow-up time, and can be compared to the 87% ORR (13 of 15 evaluable patients) who were priorly presented at the American Society of Hematology (ASH) 2020 Annual Meeting.
Eight of 18 (44%) assessed patients partly got a response (PR) and two patients (11%) consisted of stable disease (SD), for a total clinical best benefit rate of 94%. The finished response rate was 39% (7 of 18 assessed patients)
The combination of cirmtuzumab and ibrutinib had had a high tolerance, with treatment usage producing harmful events and blood aberrations consistent with, or moderately lower than those reported for the only ibrutinib. No dose-limiting toxicities have been established and no serious negative scenarios are linked to cirmtuzumab alone.
Positive Interim data combined with a low rate of toxicity as compared to the only ibrutinib has surged investor interest for Oncternal Therapeutics, with ONCT stock price rising immensely at last check.